Furthermore, high HLA-E expression in the lymph nodes of patients with a wide range of B cell malignancies (CLL and mantle cell, Burkitt, DLBCL, and follicular NHLs) indicates disruption of this immune checkpoint may be broadly applicable to a range of NK cell therapies in patients with different types of B cell malignancies. This evidence concerns the gene HLA-E and B-cell chronic lymphocytic leukemia.